Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 3
1947 2
1949 5
1950 3
1951 6
1952 6
1953 8
1954 6
1955 7
1956 4
1957 7
1958 3
1959 4
1960 2
1961 8
1962 6
1963 4
1964 2
1975 10
1976 19
1977 17
1978 17
1979 23
1980 21
1981 38
1982 98
1983 78
1984 126
1985 192
1986 250
1987 270
1988 290
1989 429
1990 501
1991 572
1992 619
1993 712
1994 749
1995 809
1996 863
1997 852
1998 865
1999 867
2000 915
2001 934
2002 875
2003 821
2004 836
2005 862
2006 912
2007 865
2008 815
2009 804
2010 867
2011 877
2012 918
2013 862
2014 909
2015 935
2016 905
2017 858
2018 816
2019 828
2020 981
2021 982
2022 883
2023 812
2024 312

Text availability

Article attribute

Article type

Publication date

Search Results

28,565 results

Results by year

Filters applied: . Clear all
Page 1
Etoposide: A rider on the cytokine storm.
Bailly C. Bailly C. Cytokine. 2023 Aug;168:156234. doi: 10.1016/j.cyto.2023.156234. Epub 2023 Jun 1. Cytokine. 2023. PMID: 37269699 Review.
Etoposide is a potent topoisomerase II poison, causing double-stranded DNA breaks which lead to cell death if they are not repaired. ...The question arises as to whether the two faces of etoposide action can apply to other topoisomerase II inhibitors....
Etoposide is a potent topoisomerase II poison, causing double-stranded DNA breaks which lead to cell death if they are not repaired. …
Etoposide (VP-16-213).
Issell BF, Crooke ST. Issell BF, et al. Cancer Treat Rev. 1979 Jun;6(2):107-24. doi: 10.1016/s0305-7372(79)80045-6. Cancer Treat Rev. 1979. PMID: 385138 Review. No abstract available.
Etoposide pharmacology.
Hande KR. Hande KR. Semin Oncol. 1992 Dec;19(6 Suppl 13):3-9. Semin Oncol. 1992. PMID: 1492225 Review.
The drug's steady state volume of distribution ranges from 5 to 17 L/m2, and it is highly bound to plasma protein with an average free plasma fraction of 6%. A number of etoposide metabolites have been confirmed or postulated. Several cell lines have been shown to acquire …
The drug's steady state volume of distribution ranges from 5 to 17 L/m2, and it is highly bound to plasma protein with an average free plasm …
Etoposide: an update.
Fleming RA, Miller AA, Stewart CF. Fleming RA, et al. Clin Pharm. 1989 Apr;8(4):274-93. Clin Pharm. 1989. PMID: 2653712 Review.
The disposition of etoposide in patients with renal and hepatic dysfunction is discussed. ...The impact of etoposide on prolonging survival in lung and testicular cancer is addressed, and studies evaluating the pharmacodynamics of etoposide are described. ...
The disposition of etoposide in patients with renal and hepatic dysfunction is discussed. ...The impact of etoposide on prolon …
Old is gold: frontline etoposide for pHLH.
Gulati N, Hermiston ML. Gulati N, et al. Blood. 2024 Mar 7;143(10):836-838. doi: 10.1182/blood.2023023123. Blood. 2024. PMID: 38451514 No abstract available.
Oral etoposide.
Phillips NC. Phillips NC. Drug Intell Clin Pharm. 1988 Nov;22(11):860-3. doi: 10.1177/106002808802201103. Drug Intell Clin Pharm. 1988. PMID: 3069425 Review.
Although no clinical trials comparing intravenous and oral etoposide in SCLC have been reported, several pharmacokinetic studies have been described. ...Other pharmacokinetic parameters are similar for both the intravenous and oral methods of administration. Based on these …
Although no clinical trials comparing intravenous and oral etoposide in SCLC have been reported, several pharmacokinetic studies have …
Podophyllotoxin derivative VP 16-213.
Arnold AM. Arnold AM. Cancer Chemother Pharmacol. 1979;3(2):71-80. doi: 10.1007/BF00254976. Cancer Chemother Pharmacol. 1979. PMID: 389478 Review.
Review of etoposide.
Phillips NC, Lauper RD. Phillips NC, et al. Clin Pharm. 1983 Mar-Apr;2(2):112-9. Clin Pharm. 1983. PMID: 6309469 Review. No abstract available.
Recent advancements in the targeted delivery of etoposide nanomedicine for cancer therapy: A comprehensive review.
Fathi-Karkan S, Arshad R, Rahdar A, Ramezani A, Behzadmehr R, Ghotekar S, Pandey S. Fathi-Karkan S, et al. Eur J Med Chem. 2023 Nov 5;259:115676. doi: 10.1016/j.ejmech.2023.115676. Epub 2023 Jul 23. Eur J Med Chem. 2023. PMID: 37499287 Review.
Etoposide (ETO), a popular anticancer drug that inhibits topoisomerase II enzymes, may be administered more effectively and efficiently due to nanomedicine. The therapeutic application of ETO is constrained by its limited solubility, weak absorption, and seve …
Etoposide (ETO), a popular anticancer drug that inhibits topoisomerase II enzymes, may be administered more effectively and ef …
Transverse melanonychia in a child receiving chemotherapy.
Stephens M, Rubin AI, Castelo-Soccio L. Stephens M, et al. Pediatr Dermatol. 2019 Jan;36(1):e60-e61. doi: 10.1111/pde.13721. Epub 2018 Dec 12. Pediatr Dermatol. 2019. PMID: 30548576 Review.
A 19-month-old boy with hemophagocytic lymphohistiocytosis treated with biweekly etoposide and dexamethasone developed transverse bands of pigment in all toenail and fingernail units consistent with transverse melanonychia. ...
A 19-month-old boy with hemophagocytic lymphohistiocytosis treated with biweekly etoposide and dexamethasone developed transverse ban …
28,565 results
You have reached the last available page of results. Please see the User Guide for more information.